Skip to main content
SpringerLink
Log in

JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England J Med 366:787–798

    Article  CAS  Google Scholar 

  2. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England J Med 366:799–807

    Article  CAS  Google Scholar 

  3. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122:4047–4053

    Article  CAS  PubMed  Google Scholar 

  4. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al (2015) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100:479–488

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N et al (2013) JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 98:722–728

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Siebolts U, Lange T, Niederwieser D, Wickenhauser C (2010) Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy. J Clin Pathol 63:370–372

    Article  PubMed  Google Scholar 

  7. Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T et al (2015) JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood 125:3352–3353

    Article  CAS  PubMed  Google Scholar 

  8. Wilkins BS, Radia D, Woodley C, El Farhi S, Keohane C, Harrison CN (2013) Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 98:1872–1876

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Molica M, Serrao A, Saracino R, Zacheo I, Stingone C, Alimena G et al (2014) Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? Ann Hematol 93:1951–1952

    Article  PubMed  Google Scholar 

  10. Wang X, Ye F, Tripodi J, HU CS, Qiu J, Najfeld V et al (2014) JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood 124:2987–95

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

AK, KH, and CW declare no conflict of interest. US and AM received honoraria from Novartis. PG is an employee from Novartis. TL, DN, and HKA received research funding and honoraria and attended advisory boards from Novartis.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University of Frankfurt, Frankfurt, Germany

    Anne Koehler

  2. Medizinische Fakultaet, University of Leipzig, Leipzig, Germany

    Karolin Hubert & Thoralf Lange

  3. Institute of Pathology, University Hospital of Halle, Halle, Germany

    Udo Siebolts & Claudia Wickenhauser

  4. Novartis Pharma AG, Basel, Switzerland

    Prashanth Gopalakrishna

  5. Department of Hematology/Oncology, University Hospital of Leipzig, Leipzig, Germany

    Dietger Niederwieser & Haifa Kathrin Al-Ali

  6. Institute of Pathology, University Hospital of Leipzig, Leipzig, Germany

    Astrid Monecke

Authors
  1. Anne Koehler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karolin Hubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thoralf Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Udo Siebolts
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudia Wickenhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prashanth Gopalakrishna
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dietger Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Astrid Monecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Haifa Kathrin Al-Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haifa Kathrin Al-Ali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koehler, A., Hubert, K., Lange, T. et al. JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. Ann Hematol 94, 1929–1930 (2015). https://doi.org/10.1007/s00277-015-2454-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2454-4

Keywords

Search

Navigation